logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Meili Sun

Central Hospital affiliated to Shandong First Medical University
H指数:28
被引数:3,700

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low dose chidamide promotes inhibitory Fcγ receptorIIb expression on monocytes in ITP: A translational study of human ITP samples and ITP murine models

低剂量沙利度胺促进ITP中单核细胞上抑制性Fcγ受体IIb的表达：一项基于人ITP样本和ITP小鼠模型的转化研究

Therapeutic Advances in Hematology
IF3.1
2026-10-010
PRE
Hongyu Zhao; Wenjing Liu; Haoyi Wang; Daqi Li; Chen Su; Meili Sun; Xinguang Liu; Lu Sun; Juan Wang; Xiaodong Qiu; Guihuan Li; Meijuan Xue; Guohai Su; Ming Hou; Yu Hou
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort

德妥帕单抗德鲁克替康与化疗在既往治疗的不可手术/转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌中的比较：TROPION-Breast01中国队列的结果

ESMO Open
IF8.3
2026-09-010
OAAI
Wang, S.; Zhang, Q.; Jiang, Z.; Tong, Z.; Li, W.; Wang, J.; Ouyang, Q.; Yao, T.; Wang, Y.; Sun, M.; Wang, X.; Wang, S.; Zang, A.; Zhang, Z.; Chen, W.; Wang, X.; Li, H.; Sheng, Y.; Zhang, B.; Liu, C.; Zhao, K.; Munegowda, M. A.; Bardia, A.; Xu, B.
A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody–drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours

一项多中心、1a/1b期剂量递增与扩展研究，评估靶向HER2的抗体-药物偶联物T-Bren（BL-M07D1）在晚期乳腺癌及其他实体瘤中的应用

EBioMedicine
IF10.8
2026-06-250
OAAI
Herui Yao; Ruihua Zhao; Xiuping Lai; Qing Wen; Meili Sun; Ying Wang; Suiwen Ye; Jun Jia; Ling Guan; Yongqiang Zhang; Xian Wang; Yahua Zhong; Jianying Huang; Mei Li; Junlan Guo; Fuguo Tian; Yuan Yuan; Sa Xiao; Hai Zhu; Yi Zhu
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial

在转移性鳞状非小细胞肺癌中使用clotistobart或多西他赛: 随机3期PRESERVE-003试验的1期

Nature Medicine
IF50
2026-03-270
OAAI
Byoung Chul Cho; Rama Balaraman; Hua-Jun Chen; Xinmin Yu; Adewale Fawole; Zhi-gang Liu; Jiliang Zhang; Long Wu; Bin Yang; Jennifer L. Leddon; John Hamm; Yanjing Huang; Lin Wu; Pinhua Pan; Preet Singh; Andrew Beardsley; Fadi Kayali; Ardalan Davarifar; Ki Hyeong Lee; Keon-Uk Park; Youngjoo Lee; Luchun Li; Xicheng Wang; Meili Sun; Yan Yu; Vikram Jain; Svetlana Shpyro; Qiong Wang; Michael Wenger; Uğur Şahin; Sergey Efuni; Shiling Song; Kun He; Pan Zheng; Yang Liu; Kai He; Tianhong Li; Mark A. Socinski; Yi-Long Wu
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial

NALIRIFOX与吉西他滨联合白蛋白结合型紫杉醇在中国晚期胰腺腺癌患者中的比较：一项随机、开放标签的II期试验

Nature Communications
IF15.7
2026-01-160
OAAI
Chuntao Gao; Yanqiao Zhang; Xiujuan Qu; Xingyun Chen; Jingdong Zhang; Heshui Wu; Meili Sun; Yong Zha; Junbin Wang; Yusheng Wang; Zhihua Li; Jinghua Gao; Rongbo Lin; Aimin Zang; Huiqing Zhang; Xianglin Yuan; Chengyou Du; Jun Zhao; Yongsheng Yang; Xuetao Shi; Wei Cheng; Bangmao Wang; Shikai Wu; Tiansuo Zhao; Jian Wang; Song Gao; Xiuchao Wang; Weidong Ma; Rui Liu; Yehui Shi; Yanping Liu; Yijiao Xie; Miao Niu; Fuchen Zhao; Jun Yu; Jihui Hao
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors

M701的开发与临床试验：一种靶向性腹腔内治疗，用于治疗源于晚期实体瘤的恶性腹水（抗EpCAM × 抗CD3双特异性抗体）

Experimental Hematology & Oncology
IF13.5
2025-11-230
OAAI
Rongrui Liu; Rongbo Lin; Ning Li; Guiling Li; Tao Zhang; Jun Zhao; Jiayi Li; Meili Sun; Ke Wang; Hanxiang An; Weijie Zhang; Huiting Xu; Shan Zeng; Mingjun Zhang; Wei Duan; Yuxian Bai; Jingdong Zhang; He Tian; Fei Yin; Yu Kang; Qi Xu; Nong Xu; Yanhong Deng; Qing Chen; Yongqiang Li; Hongying Yang; Fang Su; Zhenghong Xiao; Xiaojun Xiang; Pengfei Zhou; Shaoyi Huang; Jing Zhang; Jianming Xu
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results

一项关于OX40激动剂BGB-A445与或不与tislelizumab（一种抗PD-1单克隆抗体）联合治疗晚期实体瘤患者的I期研究：剂量递增结果

Cancer Chemotherapy and Pharmacology
IF2.3
2025-10-080
OA
Jayesh Desai; Sanjeev Deva; Bo Gao; Kunyu Yang; Kenneth J. O’Byrne; Meili Sun; Tianshu Liu; Tarek Meniawy; Xinmin Yu; Mark Voskoboynik; Diwakar Davar; Marco Matos; Shiangjiin Leaw; Tahmina Rahman; Xiaofei Qu; Hugh Giovinazzo; Xin Chen; Yan Dong; Daphne Day
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial

Tecotabart vedotin在Claudin 18.2阳性晚期胃/胃食管结合部癌中的研究：一项贝叶斯1/2期临床试验

European Journal of Cancer
IF7.1
2025-09-200
PRE
Chunmei Bai; Yi Zheng; Meili Sun; Jieer Ying; Fuxiang Zhou; Yiyi Yu; Ligang Xing; Yanqiao Zhang; Jinhua Wen; Heshui Wu; Xiuli Yang; Lixin Wan; Shiwei Guo; Rusen Zhao; Zhizhen Zhu; Wei Shen; Qi Wang; Shanzhi Gu; Hao Wu; Weichang Chen; Jin Xia; Jun Zhao; Xiaofang Dong; Wenhui Lou; Kuirong Jiang; Zhiye Zhang; Xiaobing Chen; Deliang Fu; Youshan Chen; Baoqing Wang; Jiaxin Liu; Yuan Ji; Shijie Yuan; Yuan Li; Zhihua Gong; Da Fei; Xia Qin; Crystal Qin; Jin Li
Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study

基于外周血动态变化clinlabomics数据开发并验证预测晚期胃癌免疫检查点抑制剂疗效的机器学习模型：一项回顾性多中心队列研究

Gastric Cancer
IF5.1
2025-09-070
PRE
Shulun Nie; Shuyi Song; Qian Xu; Xin Dai; Aina Liu; Meili Sun; Lei Cong; Jing Liang; Zimin Liu; Jing Lv; Zhen Li; Jinling Zhang; Fangli Cao; Linli Qu; Haiyan Liu; Lu Yue; Yi Zhai; Song Li; Lian Liu
Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies

IBI351 (fulzerasib) 单药治疗未使用KRASG12C抑制剂的中国KRASG12C-mutated转移性结直肠癌患者的疗效和安全性: 两项研究的I期汇总分析

Signal Transduction and Targeted Therapy
IF52.7
2025-07-250
OAAI
Ying Yuan; Yanhong Deng; Yongdong Jin; Zengqing Guo; Yueyin Pan; Cunji Wang; Zhiwu Wang; Yi Hu; Dong Hua; Xiangjiao Meng; Zhiye Zhang; Mingfang Zhao; Xiaorong Dong; Dingzhi Huang; Xiaoyan Li; Lian Liu; Meili Sun; Huijuan Wang; Xiuwen Wang; Nong Yang; Mingjun Zhang; Sheng Hu; Dongde Wu; Jingjing Huang; Sujie Zhang; Mengna Huang; Kefeng Ding
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

CLDN18.2靶向抗体-药物偶联物IBI343治疗晚期胃或胃食管交界处腺癌: 1期试验

Nature Medicine
IF50
2025-07-160
OA
Jia Liu; Jianwei Yang; Yuping Sun; Jifang Gong; Jinbo Yue; Yueyin Pan; Meili Sun; Rongfeng Song; Xiuying Xiao; Andrea Tazbirkova; Jian Ruan; Zhenyang Liu; Zimin Liu; Zhihua Li; Lili Sheng; Yanru Qin; Jieer Ying; Xianjun Yu; Jian Zhang; Yiping Mou; Chuangxin Lu; Ping Chen; Suyi Li; Jie Li; Xiujuan Qu; Ting Deng; Juan Du; Aiping Zhou; Enxiao Li; Xianglin Yuan; Xinjun Liang; Weiming Yu; Michelle Morris; Yang Luo; Xin Zhao; Yingmei Guo; Hui Zhou; Lin Shen
A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial

一种靶向EGFR和HER3的双特异性抗体药物偶联物在转移性食管鳞状细胞癌中的研究：一项1b期临床试验。Nat. Med

Nature Medicine
IF50
2025-07-100
OAAI
Chang Liu; Dan Liu; Yinghua Ji; Meili Sun; Shegan Gao; Xuelei Ma; Diansheng Zhong; Ji Zhu; Yanshuo Cao; Changsong Qi; Miao Zhang; Panpan Zhang; Ran Xue; Zhi Peng; Jun Zhou; Sai Ge; Ming Lu; Jiajia Yuan; Yakun Wang; Zhenghang Wang; Jian Li; Xiaotian Zhang; Yi Zhu; Hai Zhu; Sa Xiao; Jifang Gong; Lin Shen; Zhihao Lu
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

利美ertenib相较于吉非替尼，作为携带EGFR敏感突变局部晚期或转移性非小细胞肺癌的一线治疗的疗效与安全性：一项随机、双盲、双模拟、III期临床试验

The Lancet Respiratory Medicine
IF0
2025-06-200
PRE
Yuankai Shi; Lin Wu; Yinghua Ji; Gongyan Chen; Baolan Li; Minghong Bi; Runxiang Yang; Liyun Miao; Guojun Zhang; Hongjun Gao; Longhua Sun; Mingjun Zhang; Shundong Cang; Meili Sun; Wenxiu Yao; Zhijie Pan; Jiuwei Cui; Yi Xiao; Qiming Wang
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial

Sugemalimab 与安慰剂，联合铂类为基础的化疗，作为转移性非小细胞肺癌的一线治疗（GEMSTONE-302）：一项双盲、随机、III期试验的4年结果

lancet oncology
IF0
2025-06-130
PRE
Caicun Zhou; Ziping Wang; Meili Sun; Lejie Cao; Zhiyong Ma; Rong Wu; Yan Yu; Wenxiu Yao; Si Sun; Jianhua Chen; Wu Zhuang; Jiuwei Cui; Xueqin Chen; You Lu; Hong Shen; Chunhong Hu; Jiwei Liu; Yunpeng Liu; Mengzhao Wang; Xingya Li; Ping Sun; Yongqian Shu; Jianying Zhou; Jingzhang Li; Kangsheng Gu; Changli Wang; Hui Zhao; Yiping Zhang; Chunling Liu; Hui Yang; Xiaochun Zhang; Rui Ma; Lin Li; Li Liang; Man Li; Jingru Wang; Qiang Wang; Bo Wang; Hangjun Dai; Qingmei Shi; Jason Yang

研究方向

暂未获取到该数据
Y
Yuping Sun
H 指数:20论文数:105被引数:1,264
J
Jiuwei Cui
H 指数:58论文数:641被引数:1.5万
M
Mingyan Zhang
H 指数:20论文数:154被引数:1,568
L
Lin Wu
H 指数:59论文数:473被引数:1.7万
Y
Yan Yu
H 指数:26论文数:158被引数:3,229
杨
杨建民
H 指数:42论文数:412被引数:7,147
C
Chunhong Hu
H 指数:36论文数:273被引数:1.0万
Y
Yi‐Long Wu
H 指数:135论文数:2,242被引数:11.1万
Y
Yueyin Pan
H 指数:45论文数:286被引数:1.0万
J
Jason Yang
H 指数:10论文数:44被引数:413